• Je něco špatně v tomto záznamu ?

Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells

ML. Gonzalez, R. Alaghehbandan, K. Pivovarcikova, K. Michalova, J. Rogala, P. Martinek, MP. Foix, EC. Mundo, E. Comperat, M. Ulamec, M. Hora, M. Michal, O. Hes,

. 2019 ; 74 (4) : 608-617. [pub] 20190131

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028077

Grantová podpora
Q39 Charles University Research Fund
FN 00669806 Charles University Research Fund

AIMS: Current available data on cytokeratin 7 (CK7) immunostaining pattern in the clear cell renal cell carcinoma (RCC) spectrum is conflicting. The aim of this study was to assess CK7 immunoreactivity within the spectrum of clear cell renal neoplasms, including clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like tumours. METHODS AND RESULTS: We analysed two clones of CK7 and two tumour blocks for a total of 75 cases divided into five distinct groups: (i) low-grade clear cell RCC, (ii) high-grade clear cell RCC, (iii) multicystic renal neoplasm of low malignant potential, (iv) clear cell RCC with cystic changes and (v) clear cell papillary RCC-like tumours. We found the highest CK7 reactivity in low-grade clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like groups, ranging from 60% to 93%. CONCLUSIONS: Our findings show that CK7 immunoreactivity in clear cell RCC is variable, and the extent of staining depends on the grade and architectural growth patterns of the tumours.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028077
003      
CZ-PrNML
005      
20190822124844.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/his.13791 $2 doi
035    __
$a (PubMed)30444288
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gonzalez, Manuel L $u Department of Pathology, University of Kansas, Medical Center, Kansas City, Kansas, USA.
245    10
$a Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells / $c ML. Gonzalez, R. Alaghehbandan, K. Pivovarcikova, K. Michalova, J. Rogala, P. Martinek, MP. Foix, EC. Mundo, E. Comperat, M. Ulamec, M. Hora, M. Michal, O. Hes,
520    9_
$a AIMS: Current available data on cytokeratin 7 (CK7) immunostaining pattern in the clear cell renal cell carcinoma (RCC) spectrum is conflicting. The aim of this study was to assess CK7 immunoreactivity within the spectrum of clear cell renal neoplasms, including clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like tumours. METHODS AND RESULTS: We analysed two clones of CK7 and two tumour blocks for a total of 75 cases divided into five distinct groups: (i) low-grade clear cell RCC, (ii) high-grade clear cell RCC, (iii) multicystic renal neoplasm of low malignant potential, (iv) clear cell RCC with cystic changes and (v) clear cell papillary RCC-like tumours. We found the highest CK7 reactivity in low-grade clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like groups, ranging from 60% to 93%. CONCLUSIONS: Our findings show that CK7 immunoreactivity in clear cell RCC is variable, and the extent of staining depends on the grade and architectural growth patterns of the tumours.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a keratin-7 $x biosyntéza $7 D053552
650    _2
$a nádory ledvin $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
700    1_
$a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.
700    1_
$a Pivovarcikova, Krystina $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
700    1_
$a Michalova, Kvetoslava $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
700    1_
$a Rogala, Joanna $u Department of Pathology, University Hospital Wroclaw, Wroclaw, Poland.
700    1_
$a Martinek, Petr $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
700    1_
$a Foix, María P $u Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Mundo, Enric C $u Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Comperat, Eva $u Department of Pathology, Hospital Tenon, Paris, Sorbonne University, Paris, France.
700    1_
$a Ulamec, Monika $u 'Ljudevit Jurak' Pathology Department, Clinical Hospital Center 'Sestre milosrdnice', Pathology Department, Medical University, Medical Faculty Zagreb, Zagreb, Croatia.
700    1_
$a Hora, Milan $u Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
700    1_
$a Michal, Michal $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
700    1_
$a Hes, Ondrej $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
773    0_
$w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 74, č. 4 (2019), s. 608-617
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30444288 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822125123 $b ABA008
999    __
$a ok $b bmc $g 1433226 $s 1066537
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 74 $c 4 $d 608-617 $e 20190131 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043
GRA    __
$a Q39 $p Charles University Research Fund
GRA    __
$a FN 00669806 $p Charles University Research Fund
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

    Možnosti archivace